Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

NCT06995677 is registered in ClinicalTrials.gov with Tyra Biosciences, Inc as lead sponsor.

NCT NCT06995677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06995677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
Lead sponsor
Tyra Biosciences, Inc
Phase
Phase 2
Overall status
Recruiting
Start date
June 27, 2025
Completion date
September 30, 2028
Enrollment
90 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

fgfr gene alterations, fgfr gene amplification, fgfr3 gene alteration, fgfr3 gene fusions, fgfr3 gene mutation, low-grade nmibc